Mark the dates
$Bionomics(BNOX.US$ BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.
BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments.
Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's registrational program in PTSD by end of the second quarter of 2024; Late-stage trial initiation is expected by the end of 2024.
BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments.
Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's registrational program in PTSD by end of the second quarter of 2024; Late-stage trial initiation is expected by the end of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment